Intuitive Surgical, Inc. (NASDAQ:ISRG) General Counsel Sells $142,500.00 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) General Counsel Gary Loeb sold 300 shares of Intuitive Surgical stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $475.00, for a total transaction of $142,500.00. Following the completion of the transaction, the general counsel now owns 1,595 shares of the company’s stock, valued at approximately $757,625. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Intuitive Surgical Stock Up 1.4 %

Shares of NASDAQ ISRG opened at $490.93 on Thursday. The company’s fifty day moving average is $461.63 and its 200-day moving average is $420.33. The stock has a market cap of $174.13 billion, a price-to-earnings ratio of 88.62, a P/E/G ratio of 5.20 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $493.97.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted $1.18 earnings per share. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ISRG shares. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price target for the company from $380.00 to $510.00 in a report on Friday, August 2nd. JPMorgan Chase & Co. raised their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Robert W. Baird raised their price target on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Stifel Nicolaus raised their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Finally, Citigroup raised their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $446.45.

Hedge Funds Weigh In On Intuitive Surgical

A number of hedge funds and other institutional investors have recently made changes to their positions in ISRG. Creekmur Asset Management LLC lifted its position in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Ridgewood Investments LLC bought a new stake in Intuitive Surgical in the 2nd quarter valued at $26,000. Able Wealth Management LLC bought a new stake in Intuitive Surgical in the 4th quarter valued at $28,000. Delos Wealth Advisors LLC lifted its position in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Finally, LRI Investments LLC bought a new stake in Intuitive Surgical in the 1st quarter valued at $30,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.